Cited by 484Antifungal resistance and susceptibilityBacterial Identification and Susceptibility TestingYeasts and Rust Fungi Studies

The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.

Progress in Antifungal Susceptibility Testing of Candida spp. by Use of Clinical and Laboratory Standards Institute Broth Microdilution Methods, 2010 to 2012

Open access

Pfaller, M. A., Diekema, D. J.·2012·Journal of Clinical Microbiology

DOI 10.1128/jcm.00937-12PMC PMC3421803

Open this paper in CoChat — free account Open PDF

Abstract

Antifungal susceptibility testing of Candida has been standardized and refined and now may play a useful role in managing Candida infections. Important new developments include validation of 24-h reading times for all antifungal agents and the establishment of species-specific epidemiological cutoff values (ECVs) for the systemically active antifungal agents and both common and uncommon species of Candida . The clinical breakpoints (CBPs) for fluconazole, voriconazole, and the echinocandins have been revised to provide species-specific interpretive criteria for the six most common species. The revised CBPs not only are predictive of clinical outcome but also provide a more sensitive means of identifying those strains with acquired or mutational resistance mechanisms. This brief review serves as an update on the new developments in the antifungal susceptibility testing of Candida spp. using Clinical and Laboratory Standards Institute (CLSI) broth microdilution (BMD) methods.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1128/jcm.00937-12

Cites

105 of 105 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
Antifungal Agents: Mode of Action, Mechanisms of Resistance, and Correlation of These Mechanisms with Bacterial Resistance
Ghannoum, M. A., & Rice, L. B. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.4.501 · Cited by 1,811
Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White, T. C., Marr, K. A., & Bowden, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.382 · Cited by 1,353
Delaying the Empiric Treatment of Candida Bloodstream Infection until Positive Blood Culture Results Are Obtained: a Potential Risk Factor for Hospital Mortality
Morrell, M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3640-3645.2005 · Cited by 1,286
Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study.
Garey, K. W., Rege, M., Pai, M. P., Mingo, D. E., Suda, K. J., Turpin, R. S., & Bearden, D. T. (2006) · Clinical Infectious Diseases · doi:10.1086/504810 · Cited by 1,171
A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without Neutropenia
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Candida and candidiasis.
Calderone, R. (2012) · ASM Press eBooks · Cited by 912
Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment
Pfaller, M. A. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.11.001 · Cited by 903
Self-citation
Epidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Self-citation
Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida Infections
Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855
Self-citation
Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences
Sanglard, D., & Odds, F. C. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00181-0 · Cited by 784
Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-Year Analysis of Susceptibilities of Candida Species to Fluconazole and Voriconazole as Determined by CLSI Standardized Disk Diffusion
Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Ellis, D., Tullio, V., Rodloff, A., Fu, W., & Ling, T. A. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02117-09 · Cited by 718
Self-citation
EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts
Rodríguez-Tudela, J. L., Arendrup, M. C., Barchiesi, F., Billé, J., Chryssanthou, E., Cuenca‐Estrella, M., Dannaoui, É., Denning, D. W., Donnelly, J. P., Dromer, F., et al. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01935.x · Cited by 651
Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus
White, T. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1482 · Cited by 612
Setting and Revising Antibacterial Susceptibility Breakpoints
Turnidge, J. D., & Paterson, D. L. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00047-06 · Cited by 580
Antifungal Susceptibility Testing: Practical Aspects and Current Challenges
Rex, J. H., Pfaller, M. A., Walsh, T. J., Chaturvedi, V., Espinel-Ingroff, A., Ghannoum, M. A., Gosey, L. L., Odds, F. C., Rinaldi, M. G., Sheehan, D. J., et al. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.643-658.2001 · Cited by 444
Self-citation
Comparison of Methods
Roundy, S., Wright, P. K., & Rabaey, J. M. (2004) · Springer eBooks · doi:10.1007/978-1-4615-0485-6_3 · Cited by 431
Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values
Turnidge, J. D., Kahlmeter, G., & Kronvall, G. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01377.x · Cited by 404
European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria
Kahlmeter, G. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg312 · Cited by 404
Has antifungal susceptibility testing come of age
Rex, J. H., & Pfaller, M. A. (2002) · Clinical Infectious Diseases · doi:10.1086/342384 · Cited by 361
Self-citation
Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria
Pfaller, M. A., Diekema, D. J., Andes, D. R., Arendrup, M. C., Brown, S. D., Lockhart, S. R., Motyl, M. R., & Perlin, D. S. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.01.004 · Cited by 340
Self-citation
A Naturally Occurring Proline-to-Alanine Amino Acid Change in Fks1p in Candida parapsilosis , Candida orthopsilosis , and Candida metapsilosis Accounts for Reduced Echinocandin Susceptibility
Garcia-Effron, G., Katiyar, S. K., Park, S., Edlind, T. D., & Perlin, D. S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00262-08 · Cited by 323
Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3-β- d -Glucan Synthase: Implication for the Existing Susceptibility Breakpoint
Garcia-Effron, G., Lee, S., Park, S., Cleary, J. D., & Perlin, D. S. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00443-09 · Cited by 323
Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: Time for harmonization of CLSI and EUCAST broth microdilution methods
Pfaller, M. A., Andes, D., Diekema, D. J., Espinel-Ingroff, A., & Sheehan, D. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.09.002 · Cited by 314
Self-citation
Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group
Rex, J. H., Pfaller, M. A., Barry, A. L., Nelson, P. W., & Webb, C. D. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.40 · Cited by 300
Self-citation
Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing
Pfaller, M. A., Diekema, D. J., & Sheehan, D. J. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.2.435-447.2006 · Cited by 300
Self-citation
The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14alpha demethylase in Candida albicans
White, T. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1488 · Cited by 292
Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis
Redding, S., Smith, J., Farinacci, G., Rinaldi, M., Fothergill, A., Rhine-Chalberg, J., & Pfaller, M. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.2.240 · Cited by 269
Self-citation
Three-Dimensional Models of Wild-Type and Mutated Forms of Cytochrome P450 14α-Sterol Demethylases from Aspergillus fumigatus and Candida albicans Provide Insights into Posaconazole Binding
Li, X., Madison, V., Chau, A. S., Loebenberg, D., Palermo, R. E., & McNicholas, P. M. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.2.568-574.2004 · Cited by 269
Correlation of MIC with Outcome for Candida Species Tested against Voriconazole: Analysis and Proposal for Interpretive Breakpoints
Pfaller, M. A., Diekema, D. J., Rex, J. H., Espinel-Ingroff, A., Johnson, E. M., Andes, D., Chaturvedi, V., Ghannoum, M. A., Odds, F. C., Rinaldi, M. G., et al. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.3.819-826.2006 · Cited by 258
Self-citation
Correlating Echinocandin MIC and Kinetic Inhibition of fks1 Mutant Glucan Synthases for Candida albicans : Implications for Interpretive Breakpoints
Garcia-Effron, G., Park, S., & Perlin, D. S. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01162-08 · Cited by 256
Correlation of MIC with Outcome for Candida Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC Breakpoints
Pfaller, M. A., Diekema, D. J., Ostrosky-Zeichner, L., Rex, J. H., Alexander, B. D., Andes, D., Brown, S. D., Chaturvedi, V., Ghannoum, M. A., Knapp, C. C., et al. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00566-08 · Cited by 250
Self-citation
Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections
Parkins, M. D., Sabuda, D. M., Elsayed, S., & Laupland, K. B. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm212 · Cited by 229
Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia
Nolte, F. S., Parkinson, T., Falconer, D. J., Dix, S. P., Williams, J. M., Gilmore, C., Geller, R., & Wingard, J. R. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.1.196 · Cited by 219
Distinct Patterns of Gene Expression Associated with Development of Fluconazole Resistance in Serial Candida albicans Isolates from Human Immunodeficiency Virus-Infected Patients with Oropharyngeal Candidiasis
Lopez-Ribot, J. L., McAtee, R. K., Lee, L. N., Kirkpatrick, W. R., White, T. C., Sanglard, D., & Patterson, T. F. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.11.2932 · Cited by 210
Breakthrough invasive candidiasis in patients on micafungin.
Pfeiffer, C. D., Garcia-Effron, G., Zaas, A. K., Perfect, J. R., Perlin, D. S., & Alexander, B. D. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02390-09 · Cited by 196
Application of Real-Time Quantitative PCR to Molecular Analysis of Candida albicans Strains Exhibiting Reduced Susceptibility to Azoles
Chau, A. S., Mendrick, C. A., Sabatelli, F. J., Loebenberg, D., & McNicholas, P. M. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.6.2124-2131.2004 · Cited by 187
Diagnostic Issues, Clinical Characteristics, and Outcomes for Patients with Fungemia
Arendrup, M. C., Sulim, S., Holm, A., Nielsen, L. B., Nielsen, S. D., Knudsen, J. D., Drenck, N. E., Christensen, J. J., & Johansen, H. K. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.00179-11 · Cited by 177
Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution.
Pfaller, M. A., Espinel-Ingroff, A., Canton, E., Castanheira, M., Cuenca-Estrella, M., Diekema, D. J., Fothergill, A., Fuller, J., Ghannoum, M., Jones, R. N., et al. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00248-12 · Cited by 174
Self-citation
Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis
Rex, J. H., Nelson, P. W., Paetznick, V. L., Lozano-Chiu, M., Espinel-Ingroff, A., & Anaissie, E. J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.1.129 · Cited by 167
Rapid, Transient Fluconazole Resistance in Candida albicans Is Associated with Increased mRNA Levels of CDR
Marr, K. A., Lyons, C. N., Rustad, T., Bowden, R. A., & White, T. C. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.10.2584 · Cited by 166
Association of fluconazole pharmacodynamics with mortality in patients with candidemia
Baddley, J. W., Patel, M., Bhavnani, S. M., Moser, S. A., & Andes, D. R. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00116-08 · Cited by 162
Molecular Mechanisms of Primary Resistance to Flucytosine in Candida albicans
Hope, W. W., Tabernero, L., Denning, D. W., & Anderson, M. J. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.11.4377-4386.2004 · Cited by 160
Comparison of Visual and Spectrophotometric Methods of Broth Microdilution MIC End Point Determination and Evaluation of a Sterol Quantitation Method for In Vitro Susceptibility Testing of Fluconazole and Itraconazole against Trailing and Nontrailing Candida Isolates
Arthington-Skaggs, B. A., Lee-Yang, W., Ciblak, M. A., Frade, J. P., Brandt, M. E., Hajjeh, R. A., Harrison, L. H., Sofair, A. N., & Warnock, A. D. W. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2477-2481.2002 · Cited by 158
Echinocandin Susceptibility Testing of Candida Species: Comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, Disk Diffusion, and Agar Dilution Methods with RPMI and IsoSensitest Media
Arendrup, M. C., Garcia-Effron, G., Lass-Flörl, C., Lopez, A. G., Rodriguez-Tudela, J.-L., Cuenca-Estrella, M., & Perlin, D. S. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01256-09 · Cited by 158
Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Echinocandins and Candida spp
Pfaller, M. A., Boyken, L. B., Hollis, R. J., Kroeger, J. S., Messer, S. A., Tendolkar, S., Jones, R. N., Turnidge, J. D., & Diekema, D. J. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.01590-09 · Cited by 154
Self-citation
Development of Fluconazole Resistance in Candida albicans Causing Disseminated Infection in a Patient Undergoing Marrow Transplantation
Marr, K. A., White, T. C., van Burik, J. H., & Bowden, R. A. (1997) · Clinical Infectious Diseases · doi:10.1086/515553 · Cited by 145
International and Multicenter Comparison of EUCAST and CLSI M27-A2 Broth Microdilution Methods for Testing Susceptibilities of Candida spp. to Fluconazole, Itraconazole, Posaconazole, and Voriconazole
Espinel‐Ingroff, A., Barchiesi, F., Cuenca‐Estrella, M., Pfaller, M. A., Rinaldi, M. G., Rodríguez-Tudela, J. L., & Verweij, P. E. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.8.3884-3889.2005 · Cited by 140
Self-citation
Triazole Cross-Resistance among Candida spp.: Case Report, Occurrence among Bloodstream Isolates, and Implications for Antifungal Therapy
Magill, S. S., Shields, C. E., Sears, C. L., Choti, M. A., & Merz, W. G. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.2.529-535.2006 · Cited by 137
FKS Mutations and Elevated Echinocandin MIC Values among Candida glabrata Isolates from U.S. Population-Based Surveillance
Zimbeck, A. J., Iqbal, N., Ahlquist, A. M., Farley, M. M., Harrison, L. H., Chiller, T., & Lockhart, S. R. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00836-10 · Cited by 136
Interpretation of Trailing Endpoints in Antifungal Susceptibility Testing by the National Committee for Clinical Laboratory Standards Method
Revankar, S. G., Kirkpatrick, W. R., McAtee, R. K., Fothergill, A. W., Redding, S. W., Rinaldi, M. G., & Patterson, T. F. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.1.153-156.1998 · Cited by 133
Clade-Specific Flucytosine Resistance Is Due to a Single Nucleotide Change in the FUR1 Gene of Candida albicans
Dodgson, A. R., Dodgson, K. J., Pujol, C., Pfaller, M. A., & Soll, D. R. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.6.2223-2227.2004 · Cited by 133
Self-citation
Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria
Pfaller, M. A., Andes, D., Arendrup, M. C., Diekema, D. J., Espinel-Ingroff, A., Alexander, B. D., Brown, S. D., Chaturvedi, V., Fowler, C. L., Ghannoum, M. A., et al. (2011) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2011.03.002 · Cited by 130
Self-citation
Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest Methods with the CLSI Broth Microdilution Method for Echinocandin Susceptibility Testing of Candida Species
Pfaller, M. A., Castanheira, M., Diekema, D. J., Messer, S. A., Moet, G. J., & Jones, R. N. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02445-09 · Cited by 127
Self-citation
Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes
Grim, S. A., Berger, K., Teng, C. B., Gupta, S., Layden, J. E., Janda, W. M., & Clark, N. M. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr511 · Cited by 119
Evaluation of Amphotericin B Interpretive Breakpoints for Candida Bloodstream Isolates by Correlation with Therapeutic Outcome
Park, B. J., Arthington-Skaggs, B. A., Hajjeh, R. A., Iqbal, N., Ciblak, M. A., Lee-Yang, W., Hairston, M. D., Phelan, M., Plikaytis, B. D., Sofair, A. N., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1287-1292.2006 · Cited by 113
Genetic Dissection of Azole Resistance Mechanisms in Candida albicans and Their Validation in a Mouse Model of Disseminated Infection
MacCallum, D. M., Coste, A., Ischer, F., Jacobsen, M. D., Odds, F. C., & Sanglard, D. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01645-09 · Cited by 98
Antifungal therapy in invasive fungal infections
Chen, S. C. ‐., Playford, E. G., & Sorrell, T. C. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.06.002 · Cited by 98
EUCAST Technical Note on fluconazole
* (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01899.x · Cited by 94
Vancomycin use--an historical review
Griffith, R. S. (1984) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/14.suppl_d.1 · Cited by 90
Mutational Analysis of Flucytosine Resistance in Candida glabrata
Edlind, T. D., & Katiyar, S. K. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00605-10 · Cited by 84
Flucytosine Resistance Is Restricted to a Single Genetic Clade of Candida albicans
Pujol, C., Pfaller, M. A., & Soll, D. R. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.262-266.2004 · Cited by 81
Self-citation
Candida glabrata Fungemia in Transplant Patients Receiving Voriconazole after Fluconazole
Alexander, B. D., Schell, W. A., Miller, J. L., Long, G. D., & Perfect, J. R. (2005) · Transplantation · doi:10.1097/01.tp.0000173771.47698.7b · Cited by 78
Antifungal drug resistance: limited data, dramatic impact?
Rogers, T. R. (2006) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2006.03.012 · Cited by 73
Comparison of the Broth Microdilution (BMD) Method of the European Committee on Antimicrobial Susceptibility Testing with the 24-Hour CLSI BMD Method for Testing Susceptibility of Candida Species to Fluconazole, Posaconazole, and Voriconazole by Use of Epidemiological Cutoff Values
Pfaller, M. A., Espinel‐Ingroff, A., Boyken, L. B., Hollis, R. J., Kroeger, J. S., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02441-10 · Cited by 73
Self-citation
Issues in antifungal susceptibility testing
Johnson, E. M. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm427 · Cited by 68
Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review
Sun, H., & Singh, N. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.09.020 · Cited by 66
Breakpoints for Susceptibility Testing Should Not Divide Wild-Type Distributions of Important Target Species
Arendrup, M. C., Kahlmeter, G., Rodrı́guez-Tudela, J. L., & Donnelly, J. P. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01624-08 · Cited by 62
Triazole and Echinocandin MIC Distributions with Epidemiological Cutoff Values for Differentiation of Wild-Type Strains from Non-Wild-Type Strains of Six Uncommon Species of Candida
Pfaller, M. A., Castanheira, M., Diekema, D. J., Messer, S. A., & Jones, R. N. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.05047-11 · Cited by 62
Self-citation
Wild-Type MIC Distributions and Epidemiological Cutoff Values for Posaconazole and Voriconazole and Candida spp. as Determined by 24-Hour CLSI Broth Microdilution
Pfaller, M. A., Boyken, L. B., Hollis, R. J., Kroeger, J. S., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02161-10 · Cited by 61
Self-citation
EUCAST Technical Note on voriconazole
* (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.02087.x · Cited by 59
Potential confusion regarding the term 'resistance' in epidemiological surveys
Simjee, S., Silley, P., Werling, H. O., & Bywater, R. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm423 · Cited by 59
The current role of the reference procedures by CLSI and EUCAST in the detection of resistance to antifungal agentsin vitro
Cuenca‐Estrella, M., & Rodrı́guez-Tudela, J. L. (2010) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.10.2 · Cited by 56
Molecular Mechanisms of Resistance to 5-Fluorocytosine in Laboratory Mutants of Candida glabrata
Vandeputte, P., Pineau, L., Larcher, G., Noel, T., Brèthes, D., Chabasse, D., & Bouchara, J.-P. (2011) · Mycopathologia · doi:10.1007/s11046-010-9342-1 · Cited by 55
Academic Health Centers
Ebert, R. H., & Brown, S. S. (1983) · New England Journal of Medicine · doi:10.1056/nejm198305193082006 · Cited by 50
Nonsense and Missense Mutations in FCY2 and FCY1 Genes Are Responsible for Flucytosine Resistance and Flucytosine-Fluconazole Cross-Resistance in Clinical Isolates of Candida lusitaniae
Florent, M., Noël, T., Ruprich‐Robert, G., Silva, B. D., Fitton‐Ouhabi, V., Chastin, C., Papon, N., & Chapeland‐Leclerc, F. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00880-08 · Cited by 50
Comparison of 24-Hour and 48-Hour Voriconazole MICs as Determined by the Clinical and Laboratory Standards Institute Broth Microdilution Method (M27-A3 Document) in Three Laboratories: Results Obtained with 2,162 Clinical Isolates of Candida spp. and Other Yeasts
Espinel‐Ingroff, A., Cantón, R., Pemán, J., Rinaldi, M. G., & Fothergill, A. W. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.00654-09 · Cited by 49
Validation of 24-Hour Fluconazole MIC Readings versus the CLSI 48-Hour Broth Microdilution Reference Method: Results from a Global Candida Antifungal Surveillance Program
Pfaller, M. A., Boyken, L. B., Hollis, R. J., Kroeger, J. S., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.01391-08 · Cited by 47
Self-citation
Rationale for Reading Fluconazole MICs at 24 Hours Rather than 48 Hours When Testing Candida spp. by the CLSI M27-A2 Standard Method
Ostrosky‐Zeichner, L., Rex, J. H., Pfaller, M. A., Diekema, D. J., Alexander, B. D., Andes, D. R., Brown, S. D., Chaturvedi, V. P., Ghannoum, M. A., Knapp, C. C., et al. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00420-08 · Cited by 45
Self-citation
Amphotericin B resistance testing of Candida spp.: a comparison of methods
Law, D. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.1.109 · Cited by 44
Role of antifungal susceptibility testing in patient management
Forrest, G. N. (2006) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e328010682c · Cited by 39
Comparison of Visual 24-Hour and Spectrophotometric 48-Hour MICs to CLSI Reference Microdilution MICs of Fluconazole, Itraconazole, Posaconazole, and Voriconazole for Candida spp.: a Collaborative Study
Espinel‐Ingroff, A., Barchiesi, F., Cuenca‐Estrella, M., Fothergill, A. W., Pfaller, M. A., Rinaldi, M. G., Rodríguez-Tudela, J. L., & Verweij, P. E. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.9.4535-4540.2005 · Cited by 39
Self-citation
Errata
Rodriguez Tudela, J. L., Donnelly, J. P., Arendrup, M. C., Arikan, S., Barchiesi, F., Billé, J., Chryssanthou, E., Cuenca-Estrella, M., Dannaoui, É., Denning, D. W., et al. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.02658_1.x · Cited by 36
Validation of 24-Hour Posaconazole and Voriconazole MIC Readings versus the CLSI 48-Hour Broth Microdilution Reference Method: Application of Epidemiological Cutoff Values to Results from a Global Candida Antifungal Surveillance Program
Pfaller, M. A., Boyken, L. B., Hollis, R. J., Kroeger, J. S., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02437-10 · Cited by 34
Self-citation
Population-Based Surveillance
(2009) · Springer eBooks · doi:10.1007/978-0-387-78665-0_6378 · Cited by 34
The Epidemiology of Invasive Candidiasis
Pfaller, M. A., & Diekema, D. J. (2014) · ASM Press eBooks · doi:10.1128/9781555817176.ch29 · Cited by 33
Self-citation
Laboratory methods for flucytosine (5-fluorocytosine)
Speller, D. C. E., Cartwright, R. Y., Evans, E. G. V., Hay, R. J., Mackenzie, D. W. R., Milne, L. J. R., Odds, F. C., Warnock, D. W., & Wingfield, H. J. (1984) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/14.1.1 · Cited by 33
Invasive Candida species infection: the importance of adequate empirical antifungal therapy
Armstrong-James, D. P. H. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm260 · Cited by 31
To Test or Not To Test: a Cost Minimization Analysis of Susceptibility Testing for Patients with Documented Candida glabrata Fungemias
Collins, C. D., Eschenauer, G. A., Salo, S. L., & Newton, D. W. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.00192-07 · Cited by 31
Real-time antifungal susceptibility screening aids management of invasive yeast infections in immunocompromised patients
Hadley, S. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/49.2.415 · Cited by 29
Utility of real-time antifungal susceptibility testing for fluconazole in the treatment of candidemia
Baddley, J. W., Patel, M., Jones, M., Cloud, G. A., Smith, A. C., & Moser, S. A. (2004) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2004.06.004 · Cited by 28
Myelofibrosis Complicated by Infection Due toCandida albicans: Emergence of Resistance to Antifungal Agents During Therapy
Mori, T., Matsumura, M., Kanamaru, Y., MIYANO, S., Hishikawa, T., Irie, S., Oshimi, K., Saikawa, T., & Oguri, T. (1997) · Clinical Infectious Diseases · doi:10.1086/516987 · Cited by 28
A Ser29Leu Substitution in the Cytosine Deaminase Fca1p Is Responsible for Clade-Specific Flucytosine Resistance in Candida dubliniensis
McManus, B. A., Moran, G. P., Higgins, J., Sullivan, D. J., & Coleman, D. C. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00607-09 · Cited by 24
Current issues in the clinical management of invasive aspergillosis – the AGIHO, DMykG, ÖGMM and PEG web‐based survey and expert consensus conference 2009
Rüping, M. J. G. T., Vehreschild, J. J., Groll, A. H., Lass‐Flörl, C., Ostermann, H., Ruhnke, M., & Cornely, O. A. (2011) · Mycoses · doi:10.1111/j.1439-0507.2010.01989.x · Cited by 24
Antifungal use in hospitalized adults in U.S. academic health centers
Pakyz, A. L., Gurgle, H. E., & Oinonen, M. J. (2011) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp100423 · Cited by 22
Echinocandin-Resistant Candida: Molecular Methods and Phenotypes
Perlin, D. S. (2011) · Current Fungal Infection Reports · doi:10.1007/s12281-011-0054-x · Cited by 20
Wild-Type MIC Distributions and Epidemiologic Cutoff Values for Fluconazole and Candida: Time for New Clinical Breakpoints?
Pfaller, M. A., & Diekema, D. J. (2010) · Current Fungal Infection Reports · doi:10.1007/s12281-010-0022-x · Cited by 16
Self-citation
Validation of 24-Hour Flucytosine MIC Determination by Comparison with 48-Hour Determination by the Clinical and Laboratory Standards Institute M27-A3 Broth Microdilution Reference Method
Lockhart, S. R., Bolden, C. B., Iqbal, N. J., & Kuykendall, R. J. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.05479-11 · Cited by 15
Current issues in the clinical management of invasive candida infections – the AGIHO, DMykG, ÖGMM and PEG web‐based survey and expert consensus conference 2009
Karthaus, M., Rüping, M. J. G. T., Cornely, O. A., Steinbach, A., Groll, A. H., Lass‐Flörl, C., Ostermann, H., Ruhnke, M., & Vehreschild, J. J. (2011) · Mycoses · doi:10.1111/j.1439-0507.2010.01988.x · Cited by 13
In Vitro Susceptibility Testing in Fungi: What is its Role in Clinical Practice?
Perkhofer, S., Mrazek, C., Hartl, L., & Lass‐Flörl, C. (2010) · Current Infectious Disease Reports · doi:10.1007/s11908-010-0134-z · Cited by 12
Consequences for Treatment
Geile, D., & Stahl, R. (1993) · Cited by 11
Utility of Antifungal Susceptibility Testing and Clinical Correlations
Diekema, D. J., & Pfaller, M. A. (2011) · Humana Press eBooks · doi:10.1007/978-1-59745-134-5_8 · Cited by 9
Self-citation
Does One Voriconazole Breakpoint Suit All Candida Species?
Arendrup, M. C., & Denning, D. W. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.00412-07 · Cited by 9
Laboratory methods for flucytosine (5-fluorocytosine). Report of a Working Group of the British Society for Mycopathology.
(1984) · PubMed · Cited by 5

Flagged first, then by citations

Research works printed but not linked: 1

PfallerMA DiekemaDJ. 2007. Azole antifungal drug cross-resistance: mechanisms, epidemiology, and clinical significance. J. Invasive Fungal Infect. 1:74–92.

Sorted by citations

Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species
Whaley, S. G., Berkow, E. L., Rybak, J. M., Nishimoto, A. T., Barker, K. S., & Rogers, P. D. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02173 · Cited by 900
The Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection
Mazuski, J. E., Tessier, J. M., May, A. K., Sawyer, R. G., Nadler, E. P., Rosengart, M. R., Chang, P. K., O’Neill, P. J., Mollen, K. P., Huston, J. M., et al. (2017) · Surgical Infections · doi:10.1089/sur.2016.261 · Cited by 604
Changes in the epidemiological landscape of invasive candidiasis
Lamoth, F., Lockhart, S. R., Berkow, E. L., & Calandra, T. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx444 · Cited by 547
Emerging Threats in Antifungal-Resistant Fungal Pathogens
Sanglard, D. (2016) · Frontiers in Medicine · doi:10.3389/fmed.2016.00011 · Cited by 435
Multidrug-resistant endemic clonal strain of Candida auris in India
Chowdhary, A., Anil Kumar, V., Sharma, C., Prakash, A., Agarwal, K., Babu, R., Dinesh, K. R., Karim, S., Singh, S. K., Hagen, F., et al. (2014) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-013-2027-1 · Cited by 373

See all 484

Authors: Pfaller, M. A., & Diekema, D. J.
Affiliations: University of Iowa (US)
ORCID: Pfaller, M. A.
Diekema, D. J.
Venue: Journal of Clinical Microbiology
Publisher: American Society for Microbiology
Published: 2012-09
Volume: 50
Issue: 9
Pages: 2846-2856
ISSN: 0095-1137 (ISSN-L)
1098-660X
DOI: 10.1128/jcm.00937-12
PMC: PMC3421803
OpenAlex: W2120299440
Cited by: 484
References: 105
Citations by year: 2026: 15 · 2025: 20 · 2024: 24 · 2023: 29 · 2022: 26 · 2021: 41 · 2020: 41 · 2019: 31 · 2018: 43 · 2017: 46 · 2016: 45 · 2015: 41 · 2014: 47 · 2013: 31 · 2012: 4
FWCI: 4.88
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: journals.asm.org/non-commercial-tdm-license (tdm)
Locations: Journal of Clinical Microbiology (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Pfizer
Eisai
Astellas Pharma
Topics: Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
Health Sciences › Medicine › Microbiology (medical) › Bacterial Identification and Susceptibility Testing
Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
Keywords: Candida, antifungal susceptibility testing, broth microdilution, epidemiological cut-off values, clinical breakpoints, fluconazole, voriconazole, echinocandins, antifungal resistance, Candida species, CLSI guidelines
MeSH terms: Antifungal Agents, Candida, Candidiasis, Humans, Microbial Sensitivity Tests

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Progress in Antifungal Susceptibility Testing of Candida spp. by Use of Clinical and Laboratory Standards Institute Broth Microdilution Methods, 2010 to 2012

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks